Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 12/20 | 0.58 |
| ▸ | FCER2 | P06734 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 14/20 | 0.55 |
| ▸ | MMP3 | P08254 | 8/20 | 0.55 |
| ▸ | MMP9 | P14780 | 4/20 | 0.53 |
| ▸ | MMP8 | P22894 | 4/20 | 0.53 |
| ▸ | MMP7 | P09237 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428861 | 1.00 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL6846291 | 1.00 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL19361059 | 0.93 | MMP1 (0.64) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL22962378 | 0.93 | MMP1 (0.64) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7439018 | 0.89 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7439020 | 0.89 | MMP1 (0.58) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL16254380 | 0.88 | CYP2D6 (0.54) | MMP1FCER2MMP2MMP3 | |
| SCHEMBL21988101 | 0.86 | MMP1 (0.63) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7762294 | 0.86 | MMP1 (0.56) | MMP1FCER2MMP2MMP3MMP9 | |
| SCHEMBL7762297 | 0.86 | MMP1 (0.56) | MMP1FCER2MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021212638-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-10-28 | — | — | WO | disclosed |
| EP-3888691-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| EP-3862023-A1 | CONJUGATES OF CELL-BINDING MOLECULES WITH CYTOTOXIC AGENTS | Hangzhou DAC Biotech Co, Ltd (CN) | 2021-08-11 | — | — | EP | disclosed |
| WO-2021076197-A1 | CONJUGATE MOLECULES | DIVERSE BIOTECH, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2020257998-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020263888-A1 | CANNABINOID CONJUGATE MOLECULES | DIVERSE BIOTECH, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020258893-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020155017-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020006722-A1 | CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-01-09 | — | — | WO | disclosed |
| WO-2018086139-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2018-05-17 | — | — | WO | disclosed |
| WO-1999045029-A1 | NEW SALT FORMS OF (2E)- 5-AMINO-5- METHYLHEX-2- ENOIC ACID N-METHYL-N-((1R)-1-(N- METHYL-N-((1R)-1-(METHYLCARBAMOYL)-2- PHENYLETHYL)CARBAMOYL)-2- (2-NAPHTYL)ETHYL)AMIDE | NOVO NORDISK A/S (DK) | 1999-09-10 | — | — | WO | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| CN-1220609-A | Growth hormone component and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis | NOVO NORDISK AS (DK) | 1999-06-23 | — | — | CN | disclosed |
| EP-0907374-A1 | GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS | NOVO NORDISK A/S (DK) | 1999-04-14 | — | — | EP | disclosed |
| CN-1211991-A | Compounds with growth hormone releasing properties | NOVO NORDISK AS (DK) | 1999-03-24 | — | — | CN | disclosed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998019699-A1 | USE OF GROWTH HORMONE OR A GROWTH HORMONE SECRETAGOGUE FOR PROMOTING BONE FORMATION | NOVO NORDISK A/S (DK) | 1998-05-14 | — | — | WO | disclosed |
| WO-1997046252-A1 | GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS | NOVO NORDISK A/S (DK) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | disclosed |